Dr. Muhammet Avcil and Imperial Bioscience lead the charge in healthcare innovation as finalists at the 2023 Great British Entrepreneur Awards, pioneering a future where transformative technology revolutionizes drug delivery and global healthcare access.

Imperial Bioscience stands as a pioneering force propelling monumental change in global healthcare. At its helm is Dr. Muhammet Avcil, a visionary thought leader driven by an unwavering mission to push the frontiers of medical innovation. His brainchild, Imperial Bioscience, is pioneering a transformative technology poised to redefine the landscape of drug delivery and healthcare access. 

Since its launch in 2016, Imperial Bioscience has etched its name in the biopharmaceutical arena through the development of its revolutionary Microarray Patch (MAP) technology. These precision-engineered patches enable the targeted and accurate delivery of drugs and vaccines through the skin. MAPs embody the promise of enhanced patient experience, improved treatment outcomes and expanded healthcare access.

The inspiration behind Imperial Bioscience is rooted in a shared vision of empowering lives through inclusive medical breakthroughs. Dr. Avcil is propelled by a steadfast resolve to bridge the chasm between pioneering scientific advances and their global reach. This vision has gained momentum through substantial funding and partnerships with world-leading research institutions to develop novel, drug-containing MAPs, bringing equitable access to life-saving interventions within closer reach.

Imperial Bioscience’s journey has been marked by significant milestones, including successful clinical trials demonstrating the potential of MAPs to elicit robust immune responses rivalling and surpassing traditional injections. Their pioneering public-private partnerships represent a shared commitment to redefining global health. 

The future is brimming with possibilities as Imperial Bioscience expands its MAP technology across diverse therapeutic domains. Through strategic alliances, portfolio growth and relentless innovation, they are actively shaping a new era of healthcare where access, experience and outcomes transcend convention. Imperial Bioscience’s vision expands beyond a service to embody a transformative experience, effecting real change through ingenuity, partnership and inclusivity.

Imperial Bioscience has been recognised as finalists in the 2023 Great British Entrepreneur Awards, known as “The Grammys of Entrepreneurship”. The awards ceremony will take place on 20th November at London’s Grosvenor House. To learn more about Imperial Bioscience and its pioneering journey, visit www.imperialbioscience.co.uk.